Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

evinacumab

EVKEEZA

evinacumab (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Ultragenyx UK Limited.

EMA: approved Cardiovascular system (C10) C10AX
Patents linked 17
Pipeline programs 6
News articles 0
Drug details — evinacumab
Class
Cardiovascular system (C10)
Route
—
Patents
17
Programs
6
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

evinacumab (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Ultragenyx UK Limited.

Key facts

INN evinacumab
Brand EVKEEZA
Mechanism Angiopoietin-related protein 3 inhibitor
Target Angiopoietin-related protein 3
Therapeutic class Cardiovascular system (C10)
ATC code C10AX
Originator Ultragenyx UK Limited

Mechanism of action

Angiopoietin-related protein 3 inhibitor

Primary target: Angiopoietin-related protein 3

Approval history

Authority Status Date
EMA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Evinacumab Phase 3 · Ultragenyx UK · Homozygous Familial Hypercholesterolemia
  2. evinacumab Phase 3 · Regeneron UK · Homozygous Familial Hypercholesterolemia
  3. Evinacumab Phase 2 · Regeneron UK · Hypercholesterolemia
  4. evinacumab Phase 2 · Regeneron UK · Hypertriglyceridemia
  5. evinacumab Phase 2 · Regeneron UK · Severe Hypertriglyceridemia (sHTG)
  6. Evinacumab Phase 1 · Regeneron UK · Healthy Volunteers

Related & competitor drugs

Browse all drugs
  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. dofetilide Cardiovascular system (C01)

Related patents

Browse patents Ultragenyx UK Limited patent hub

  1. US 11944658

    Methods of heat inactivation of adenovirus

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11771748

    Methods for treating tumor-induced osteomalacia

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11753369

    Creatine prodrugs, compositions and methods of use thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11332438

    Creatine prodrugs, compositions and methods of use thereof

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11202822

    Methods for treating hypophosphatemic disorders

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11013774

    Methods of heat inactivation of adenovirus

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10889607

    Sialic acid analogs

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10639360

    Methods for treating hypophosphatemic disorders

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10457701

    Sialic acid analogs

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10385085

    Crystal forms of sialic acid or salt or solvate thereof

    Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10065981

    Sialic acid analogs

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9937243

    Sialylated glycoprotein compositions and uses thereof

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9687532

    Sialylated glycoprotein compositons and uses thereof

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9457067

    Sialylated glycoprotein compositions and uses thereof

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9457068

    Sialylated glycoprotein compositions and uses thereof

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9221858

    Sialic acid analogs

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8840926

    Sialic acid analogs

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is evinacumab?

evinacumab (EVKEEZA) is a angiopoietin-related protein 3 inhibitor. Associated with Ultragenyx UK Limited.

What is the brand name for evinacumab?

EVKEEZA is a marketed brand name for evinacumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.